TG4050 not checked

Transgene

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1/2 trial completes
Trials
1 active
2 in total · 1 in the EU

What this is

How it works
How it works isn't classified yet
How it’s given
“Subcutaneous injections weekly for the first 6 weeks and then every 3 weeks”In the company’s words, NCT04183166 on ClinicalTrials.gov
Tested for
Squamous Cell Carcinoma of Head and Neck
Main trialPhase 1/2
“This is a multicenter, open-label, two arms, randomized, phase I/II study evaluating the safety and tolerability as well as some activity parameters of TG4050 in patients with squamous cell carcinoma of the head and neck (SCCHN).”In the company’s words, NCT04183166 on ClinicalTrials.gov

Other drugs for Squamous Cell Carcinoma of Head and Neck

All 199 drugs for Squamous Cell Carcinoma of Head and Neck

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 1/2Active, not recruiting 30 Dec 2027 A Clinical Trial Evaluating TG4050 in Head and Neck Cancer
Phase 1Completed 8 Oct 2024 A Trial Evaluating TG4050 in Ovarian Carcinoma.
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow TG4050

Following is part of Solo: you see every change to TG4050 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in